Interferences in Therapeutic Drug Monitoring

Dasgupta, Amitava; Wahed, Amer

doi:10.1016/b978-0-12-407821-5.00015-2

Cited by 1 publication

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For TAC samples (Figure D), a small positive bias of 2.64 ± 5.49% was observed with the limit of agreement ranging from −33.03 to +36.32%. This suggests that our LDI-MS method has a significantly lower bias compared to the commonly used immunoassays, of which the positive bias can vary 10%–40% depending on the immunosuppressive drug and type of immunoassay . Although a few measurements out of 40 subjects were beyond the limit of agreement, the 95% CI of the mean bias included zero by ranging from −3.57% to +3.65% for CsA and −2.85% to +8.14% for TAC, revealing that there was no statistically significant difference between the LDI-MS method and the LC–MS/MS method .…”

Section: Resultsmentioning

confidence: 81%

“…This suggests that our LDI-MS method has a significantly lower bias compared to the commonly used immunoassays, of which the positive bias can vary 10%−40% depending on the immunosuppressive drug and type of immunoassay. 49 Although a few measurements out of 40 subjects were beyond the limit of agreement, the 95% CI of the mean bias included zero by ranging from −3.57% to +3.65% for CsA and −2.85% to +8.14% for TAC, revealing that there was no statistically significant difference between the LDI-MS method and the LC−MS/MS method. 50 This result shows that the agreement between the two analytical methods is sufficient enough to be fully interconvertible.…”

mentioning

confidence: 90%

See 1 more Smart Citation

Quantitative Analysis of Immunosuppressive Drugs Using Tungsten Disulfide Nanosheet-Assisted Laser Desorption Ionization Mass Spectrometry

Joh

Son

et al. 2021

ACS Nano

View full text Add to dashboard Cite

For organ transplantation patients, the therapeutic drug monitoring (TDM) of immunosuppressive drugs is essential to prevent the toxicity or rejection of the organ. Currently, TDM is done by immunoassays or liquid chromatography–tandem mass spectrometry (LC–MS/MS) methods; however, these methods lack specificity or are expensive, require high levels of skill, and offer limited sample throughput. Although matrix-assisted (MA) laser desorption ionization (LDI) mass spectrometry (MS) can provide enhanced throughput and cost-effectiveness, its application in TDM is limited due to the limitations of the matrixes such as a lack of sensitivity and reproducibility. Here, we present an alternative quantification method for the TDM of the immunosuppressive drugs in the blood of organ transplant patients by utilizing laser desorption ionization mass spectrometry (LDI-MS) based on a tungsten disulfide nanosheet, which is well-known for its excellent physicochemical properties such as a strong UV absorbance and high electron mobility. By adopting a microliquid inkjet printing system, a high-throughput analysis of the blood samples with enhanced sensitivity and reproducibility was achieved. Furthermore, up to 80 cases of patient samples were analyzed and the results were compared with those of LC–MS/MS by using Passing–Bablok regression and Bland–Altman analysis to demonstrate that our LDI-MS platform is suitable to replace current TDM techniques. Our approach will facilitate the rapid and accurate analysis of blood samples from a large number of patients for immunosuppressive drug prescriptions.

show abstract

Section: Resultsmentioning

confidence: 81%

mentioning

confidence: 90%